157590-60-8

Basic information

• Product Name: 4-BROMO-5-(TRIFLUOROMETHYL)BENZENE-1,2-DIAMINE
• Synonyms: 4-BROMO-5-(TRIFLUOROMETHYL)BENZENE-1,2-DIAMINE;4-Bromo-5-fluorobenzene-1,2-diamine;2-Amino-4-bromo-5-(trifluoromethyl)phenylamine
• CAS NO: 157590-60-8
• Molecular Formula: C₇H₆BrF₃N₂
• Molecular Weight: 255.04
• Mol File: 157590-60-8.mol

Chemical Properties

• Boiling Point: 284.5±40.0 °C(Predicted)
• Appearance: /
• Density: 1.774±0.06 g/cm3(Predicted)
• Storage Temp.: Keep in dark place,Inert atmosphere,Room temperature
• PKA: 2.23±0.10(Predicted)
• CAS DataBase Reference: 4-BROMO-5-(TRIFLUOROMETHYL)BENZENE-1,2-DIAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-5-(TRIFLUOROMETHYL)BENZENE-1,2-DIAMINE(157590-60-8)
• EPA Substance Registry System: 4-BROMO-5-(TRIFLUOROMETHYL)BENZENE-1,2-DIAMINE(157590-60-8)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 157590-60-8(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
4-BROMO-5-(TRIFLUOROMETHYL)BENZENE-1,2-DIAMINE is used as a building block in organic synthesis for the creation of complex molecules. Its unique structure allows for various chemical reactions, making it a valuable component in the synthesis of advanced organic compounds.
Used in Pharmaceutical Development:
In the pharmaceutical industry, 4-BROMO-5-(TRIFLUOROMETHYL)BENZENE-1,2-DIAMINE is used as a key intermediate in the development of new drugs. Its presence in the molecular structure can influence the pharmacological properties of the final product, contributing to the discovery of novel therapeutic agents.
Used in Dye Production:
4-BROMO-5-(TRIFLUOROMETHYL)BENZENE-1,2-DIAMINE is used as a starting material in the production of dyes. Its chemical properties enable the creation of dyes with specific color characteristics, making it a useful component in the dye manufacturing process.
Used in Material Science:
In material science, 4-BROMO-5-(TRIFLUOROMETHYL)BENZENE-1,2-DIAMINE is used for the development of new materials with unique properties. Its incorporation into the molecular structure can enhance the performance of materials in various applications, such as coatings, adhesives, and polymers.

Upstream product

• 683241-86-3 4-bromo-2-nitro-5-(trifluoromethyl)aniline 
• 1025812-78-5 N-(3-bromo-4-(trifluoromethyl)phenyl)acetamide 
• 172215-91-7 3-bromo-4-(trifluoromethyl)aniline 
• 393-36-2 4-bromo-3-(trifluoromethyl)aniline 
• 157554-76-2 N-[4-bromo-2-nitro-5-(trifluoromethyl)phenyl]acetamide 
• 41513-05-7 N-(4-bromo-3-trifluoromethylphenyl)acetamide 
• 1026267-58-2 5-Bromo-2-nitro-4-trifluoromethyl-phenylamine 
• 1028299-41-3 N-(5-bromo-2-nitro-4-(trifluoromethyl)phenyl)acetamide 

Downstream Products

• 683243-08-5 N-(4-(trifluoromethyl)benzyl)-6-(trifluoromethyl)-2-(4-(3-(trifluoromethyl)pyridin-2-yl)piperazin-1-yl)-1-((2-(trimethylsilyl)ethoxy)methyl)-1H-benzo[d]imidazol-5-ylamine 
• 1345117-61-4 2,6-difluoro-N-(5-(6-(trifluoromethyl)benzo[c][1,2,5]thiadiazol-5-yl)pyridin-2-yl)benzamide 

Relevant articles and documents

INDAZOLES AS LRRK2 INHIBITORS

The present invention is directed to indazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.

COMPOUNDS THAT MODULATE INTRACELLULAR CALCIUM

Described herein are compounds and pharmaceutical compositions containing such compounds, which modulate the activity of store-operated calcium (SOC) channels. Also described herein are methods of using such SOC channel modulators, alone and in combination with other compounds, for treating diseases or conditions that would benefit from inhibition of SOC channel activity.

NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS FOR OPIOID RECEPTORS

This invention relates to novel compounds which are antagonists or inverse agonists at one or more of the opioid receptors, to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy.

The development of benzimidazoles as selective rho kinase inhibitors

Rho Kinase (ROCK) is a serine/threonine kinase whose inhibition could prove beneficial in numerous therapeutic areas. We have developed a promising class of ATP-competitive inhibitors based upon a benzimidazole scaffold, which show excellent potency toward ROCK (IC50 10 nM). This report details the optimization of selectivity for ROCK over other related kinases such as Protein kinase A (PKA).

Benzimidazole Modulators of VR1

The invention is directed to compounds of Formula (I): to pharmaceutical compositions containing such compounds and to methods of treatment using them.

Design of potent, orally available antagonists of the transient receptor potential vanilloid 1. Structure-activity relationships of 2-piperazin-1-yl-1H- benzimidazoles

The vanilloid receptor-1 (VR1 or TRPV1) is a membrane-bound, nonselective cation channel that is predominantly expressed by peripheral neurons sensing painful stimuli. TRPV1 antagonists produce antihyperalgesic effects in animal models of inflammatory and neuropathic pain. Herein, we describe the synthesis and the structure-activity relationships of a series of 2-(4-pyridin-2- ylpiperazin-1-yl)-1H-benzo-[d]imidazoles as novel TRPV1 antagonists. Compound 46ad was among the most potent analogues in this series. This compound was orally bioavailable in rats and was efficacious in blocking capsaicin-induced flinch in rats in a dose-dependent manner. Compound 46ad also reversed thermal hyperalgesia in a model of inflammatory pain, which was induced by complete Freund's adjuvant (CFA).

BENZIMIDAZOLE DERIVATIVES AND THEIR USE AS VANILLOID RECEPTOR LIGANDS

Compounds of formula (I) are useful in the treatment of vanilloid-receptor-meditated diseases, such as inflammatory or neuropathic pain and diseases involving sensory nerve function such as asthma, rheumatoid arthritis, osteoarthritis, inflammatory bowel disorders, urinary incontinence, migraine and psoriasis.

Synthesis and structure-activity relationships of substituted 1,4- dihydroquinoxaline-2,3-diones: Antagonists of N-methyl-D-aspartate (NMDA) receptor glycine sites and non-NMDA glutamate receptors

A series of mono-, di-, tri-, and tetrasubstituted 1,4- dihydroquinoxaline-2,3-diones (QXs) were synthesized and evaluated as antagonists at N-methyl-D-aspartate (NMDA)/glycine sites and α-amino-3- hydroxy-5-methylisoxazole-4-propionic acid-preferring non-NMDA receptors. Antagonist potencies were measured by electrical assays in Xenopus oocytes expressing rat whole brain poly(A)+ RNA. Trisubstituted QXs 17a (ACEA 1021), 17b (ACEA 1031), 24a, and 27, containing a nitro group in the 5 position and halogen in the 6 and 7 positions, displayed high potency (K(b) ~ 6-8 nM) at the glycine site, moderate potency at non-NMDA receptors (K(b) = 0.9-1.5 μM), and the highest (120-250-fold) selectivity in favor of glycine site antagonism over non-NMDA receptors. Tetrasubstituted QXs 17d,e were more than 100-fold weaker glycine site antagonists than the corresponding trisubstituted QXs with F being better tolerated than Cl as a substituent at the 8 position. Di- and monosubstituted QXs showed progressively weaker antagonism compared to trisubstituted analogues. For example, removal of the 5-nitro group of 17a results in a ~100-fold decrease in potency (10a,b,z), while removal of both halogens from 17a results in a ~3000-fold decrease in potency (10v). In terms of steady-state inhibition, most QX substitution patterns favor antagonism at NMDA/glycine sites over antagonism at non-NMDA receptors. Among the QXs tested, only 17i was slightly selective for non- NMDA receptors.